Sun Y, Guan X, Wang H, et al. - Researchers conducted this prospective, multi‐center, parallel controlled, double‐blind randomized clinical trial to assess whether oral α‐lipoic acid (ALA) in combination with NB‐UVB phototherapy has efficacy and safety in the treatment of nonsegmental stable vitiligo. This inquiry was performed in seven comprehensive tertiary hospitals in China. The patients were randomly assigned to oral ALA group or placebo group at a dose of 300 mg daily for 6 months. NB‐UVB phototherapy was received by all three times weekly. Using a 4‐point grading scale of improvement: > 98%, 50‐98%, 10‐49%, < 10%, experts assessed repigmentation rate. Of 133 patients enrolled, 72 were in the treatment group and 61 in the control group. In the treatment group, ≥ 50% improvement at 1‐month following enrollment (M1) was achieved by 2.04% (1/49) patients, and the percentage of patients rose to 8.51% (4/47), 14.0% (6/43), and 37.8% (14/37) at M2, M3, and M6, respectively. At all timepoints, similar percentages were reported in the control group. Between these two groups, there was no significant difference. Overall, findings showed no additional benefit of ALA to NB‐UVB therapy in the management of nonsegmental stable vitiligo.